A retrospective study on the same population by Shaw et al. suggested that overall survival for patients with advanced ALK-positive NSCLC was significantly longer in patients given Crizotinib second- or third-line compared to Crizotinib-naïve patients, whose prognosis was very similar to the general NSCLC population. The gene discussed is ALK; the disease is non-small cell lung carcinoma.